1
|
Amin W, Linkov F, Landsittel DP, Silverstein JC, Bashara W, Gaudioso C, Feldman MD, Pass HI, Melamed J, Friedberg JS, Becich MJ. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Res 2018; 7:1184. [PMID: 30410729 DOI: 10.12688/f1000research.15512.1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/27/2018] [Indexed: 12/30/2022] Open
Abstract
Background: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US. Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for peritoneal presentation. The overarching aim of this study is to examine survival of the cohort of patients with malignant mesothelioma enrolled in the National Mesothelioma Virtual Bank (NMVB). Methods: 888 cases of pleural and peritoneal mesothelioma cases were selected from the NMVB database, which houses data and associated biospecimens for over 1400 cases that were diagnosed from 1990 to 2017. Kaplan Meier's method was performed for survival analysis. The association between prognostic factors and survival was estimated using Cox Hazard Regression method and using R software for analysis. Results: The median overall survival (OS) rate of all MM patients, including pleural and peritoneal mesothelioma cases is 15 months (14 months for pleural and 31 months for peritoneal). Significant prognostic factors associated with improved survival of malignant mesothelioma cases in this NMVB cohort were younger than 45, female gender, epithelioid histological subtype, stage I, peritoneal occurrence, and having combination treatment of surgical therapy with chemotherapy. Combined surgical and chemotherapy treatment was associated with improved survival of 23 months in comparison to single line therapies. Conclusions: There has not been improvement in the overall survival for patients with malignant mesothelioma over many years with current available treatment options. Our findings show that combined surgical and chemotherapy treatment in peritoneal mesothelioma is associated with improved survival compared to local therapy alone.
Collapse
Affiliation(s)
- Waqas Amin
- Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, 15206, USA
| | - Faina Linkov
- Obstetrics, Gynecology and Reproductive Science,, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | | | | | - Wiam Bashara
- Department of Pathology and Lab. Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA
| | - Carmelo Gaudioso
- Department of Pathology and Lab. Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.,Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
| | - Michael D Feldman
- Department of Pathology and Laboratory Medicine, The Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA
| | - Harvey I Pass
- Department of Surgery, New York University Langone Health, New York, NY, 10016, USA
| | - Jonathan Melamed
- Department of Pathology, New York University Langone Health, New York, NY, 10016, USA
| | - Joseph S Friedberg
- Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21201, USA
| | - Michael J Becich
- Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, 15206, USA
| |
Collapse
|
2
|
Amin W, Linkov F, Landsittel DP, Silverstein JC, Bashara W, Gaudioso C, Feldman MD, Pass HI, Melamed J, Friedberg JS, Becich MJ. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Res 2018; 7:1184. [PMID: 30410729 PMCID: PMC6198263 DOI: 10.12688/f1000research.15512.3] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/23/2019] [Indexed: 12/16/2022] Open
Abstract
Background: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US. Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for peritoneal presentation. The overarching aim of this study is to examine survival of the cohort of patients with malignant mesothelioma enrolled in the National Mesothelioma Virtual Bank (NMVB). Methods: 888 cases of pleural and peritoneal mesothelioma cases were selected from the NMVB database, which houses data and associated biospecimens for over 1400 cases that were diagnosed from 1990 to 2017. Kaplan Meier’s method was performed for survival analysis. The association between prognostic factors and survival was estimated using Cox Hazard Regression method and using R software for analysis. Results: The median overall survival (OS) rate of all MM patients, including pleural and peritoneal mesothelioma cases is 15 months (14 months for pleural and 31 months for peritoneal). Significant prognostic factors associated with improved survival of malignant mesothelioma cases in this NMVB cohort were younger than 45, female gender, epithelioid histological subtype, stage I, peritoneal occurrence, and having combination treatment of surgical therapy with chemotherapy. Combined surgical and chemotherapy treatment was associated with improved survival of 23 months in comparison to single line therapies. Conclusions: There has not been improvement in the overall survival for patients with malignant mesothelioma over many years with current available treatment options. Our findings show that combined surgical and chemotherapy treatment in peritoneal mesothelioma is associated with improved survival compared to local therapy alone.
Collapse
Affiliation(s)
- Waqas Amin
- Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, 15206, USA
| | - Faina Linkov
- Obstetrics, Gynecology and Reproductive Science,, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | | | | | - Wiam Bashara
- Department of Pathology and Lab. Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA
| | - Carmelo Gaudioso
- Department of Pathology and Lab. Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.,Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
| | - Michael D Feldman
- Department of Pathology and Laboratory Medicine, The Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA
| | - Harvey I Pass
- Department of Surgery, New York University Langone Health, New York, NY, 10016, USA
| | - Jonathan Melamed
- Department of Pathology, New York University Langone Health, New York, NY, 10016, USA
| | - Joseph S Friedberg
- Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21201, USA
| | - Michael J Becich
- Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, 15206, USA
| |
Collapse
|
3
|
Amin W, Linkov F, Landsittel DP, Silverstein JC, Bshara W, Gaudioso C, Feldman MD, Pass HI, Melamed J, Friedberg JS, Becich MJ. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Res 2018; 7:1184. [PMID: 30410729 PMCID: PMC6198263 DOI: 10.12688/f1000research.15512.2] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/23/2019] [Indexed: 07/26/2023] Open
Abstract
Background: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US. Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for peritoneal presentation. The overarching aim of this study is to examine survival of the cohort of patients with malignant mesothelioma enrolled in the National Mesothelioma Virtual Bank (NMVB). Methods: 888 cases of pleural and peritoneal mesothelioma cases were selected from the NMVB database, which houses data and associated biospecimens for over 1400 cases that were diagnosed from 1990 to 2017. Kaplan Meier's method was performed for survival analysis. The association between prognostic factors and survival was estimated using Cox Hazard Regression method and using R software for analysis. Results: The median overall survival (OS) rate of all MM patients, including pleural and peritoneal mesothelioma cases is 15 months (14 months for pleural and 31 months for peritoneal). Significant prognostic factors associated with improved survival of malignant mesothelioma cases in this NMVB cohort were younger than 45, female gender, epithelioid histological subtype, stage I, peritoneal occurrence, and having combination treatment of surgical therapy with chemotherapy. Combined surgical and chemotherapy treatment was associated with improved survival of 23 months in comparison to single line therapies. Conclusions: There has not been improvement in the overall survival for patients with malignant mesothelioma over many years with current available treatment options. Our findings show that combined surgical and chemotherapy treatment in peritoneal mesothelioma is associated with improved survival compared to local therapy alone.
Collapse
Affiliation(s)
- Waqas Amin
- Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, 15206, USA
| | - Faina Linkov
- Obstetrics, Gynecology and Reproductive Science,, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | | | | | - Wiam Bshara
- Department of Pathology and Lab. Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA
| | - Carmelo Gaudioso
- Department of Pathology and Lab. Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA
- Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
| | - Michael D. Feldman
- Department of Pathology and Laboratory Medicine, The Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA
| | - Harvey I. Pass
- Department of Surgery, New York University Langone Health, New York, NY, 10016, USA
| | - Jonathan Melamed
- Department of Pathology, New York University Langone Health, New York, NY, 10016, USA
| | - Joseph S. Friedberg
- Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21201, USA
| | - Michael J. Becich
- Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, 15206, USA
| |
Collapse
|